{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:16:01Z","timestamp":1790716561580,"version":"4.1.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.radonc.2026.111711","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T23:58:44Z","timestamp":1785283124000},"page":"111711","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Integration of radiation therapy with systemic treatments in head and neck cancer: expert opinion and roadmap to consensus"],"prefix":"10.1016","volume":"223","author":[{"given":"Carlotta","family":"Becherini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8083-4069","authenticated-orcid":false,"given":"Marco","family":"Banini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Blanchard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Brana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1648-1473","authenticated-orcid":false,"given":"Melvin L.K.","family":"Chua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1145-6033","authenticated-orcid":false,"given":"Jesper Grau","family":"Eriksen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8072-4388","authenticated-orcid":false,"given":"Shao Hui","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8604-4271","authenticated-orcid":false,"given":"Vincent","family":"Gregoire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Licitra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-2580","authenticated-orcid":false,"given":"Laura Deborah","family":"Locati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4802-1102","authenticated-orcid":false,"given":"Brigette","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6369-9742","authenticated-orcid":false,"given":"Jean-Pascal","family":"Machiels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Saintigny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0512-549X","authenticated-orcid":false,"given":"Ingeborg","family":"Tinhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Livi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6014-348X","authenticated-orcid":false,"given":"Kevin J.","family":"Harrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8999-5208","authenticated-orcid":false,"given":"Pierluigi","family":"Bonomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"29","key":"10.1016\/j.radonc.2026.111711_b0005","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1200\/JCO.2015.62.3157","article-title":"Transoral endoscopic head and neck surgery and its role within the multidisciplinary treatment paradigm of oropharynx cancer: robotics, lasers, and clinical trials","volume":"33","author":"Holsinger","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"10.1016\/j.radonc.2026.111711_b0010","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1200\/JCO-24-02755","article-title":"Transoral robotic surgery in the multidisciplinary care of patients with oropharyngeal squamous cell carcinoma: ASCO guideline","volume":"43","author":"Holsinger","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"29","key":"10.1016\/j.radonc.2026.111711_b0015","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1200\/JCO.2015.61.2994","article-title":"Advances in radiotherapy for head and neck cancer","volume":"33","author":"Gr\u00e9goire","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"10.1016\/j.radonc.2026.111711_b0020","first-page":"e254","article-title":"Proton therapy for head and neck cancer: expanding the therapeutic window","volume":"18","author":"Leeman","year":"2017","journal-title":"LancetOncol"},{"issue":"29","key":"10.1016\/j.radonc.2026.111711_b0025","doi-asserted-by":"crossref","first-page":"3305","DOI":"10.1200\/JCO.2015.62.0963","article-title":"Current treatment options for recurrent or metastatic head and neck squamous cell carcinoma","volume":"33","author":"Sacco","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2026.111711_b0030","article-title":"Updates on treatments and management of nasopharyngeal carcinoma","volume":"45","author":"Chua","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book Am Soc Clin Oncol Annu Meet"},{"issue":"2","key":"10.1016\/j.radonc.2026.111711_b0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(14)71200-8","article-title":"Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial","volume":"16","author":"Giralt","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2026.111711_b0040","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/S1470-2045(14)71198-2","article-title":"Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial","volume":"16","author":"Mes\u00eda","year":"2015","journal-title":"Lancet Oncol"},{"issue":"27","key":"10.1016\/j.radonc.2026.111711_b0045","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1200\/JCO.2013.53.5633","article-title":"Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522","volume":"32","author":"Ang","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111711_b0050","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2012.30.15_suppl.5500","article-title":"DeCIDE: A phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2\/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN)","volume":"30","author":"Cohen","year":"2012","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111711_b0055","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/annonc\/mdt461","article-title":"A randomized phase III trial comparing induction chemotherapy followed by chemoradiotherapy versus chemoradiotherapy alone as treatment of unresectable head and neck cancer","volume":"25","author":"Hitt","year":"2014","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"11","key":"10.1016\/j.radonc.2026.111711_b0060","first-page":"1565","article-title":"Radiotherapy plus cisplatin with or without lapatinib for non-human papillomavirus head and neck carcinoma: a phase 2 randomized clinical trial","volume":"9","author":"Wong","year":"2023","journal-title":"JAMAOncol"},{"issue":"3","key":"10.1016\/j.radonc.2026.111711_b0065","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1093\/annonc\/mdu003","article-title":"Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent\/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I\/II ADVANTAGE trial (phase II part)","volume":"25","author":"Vermorken","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111711_b0070","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ejca.2022.10.023","article-title":"Afatinib maintenance therapy following post-operative radiochemotherapy in head and neck squamous cell carcinoma: results from the phase III randomised double-blind placebo-controlled study BIB2992ORL (GORTEC 2010-02)","volume":"178","author":"Racadot","year":"2023","journal-title":"Eur J Cancer"},{"issue":"34","key":"10.1016\/j.radonc.2026.111711_b0075","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.19.00555","article-title":"Phase III randomized trial of chemotherapy with or without bevacizumab in patients with recurrent or metastatic head and neck cancer","volume":"37","author":"Argiris","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111711_b0080","first-page":"75","article-title":"The dogma of cetuximab and radiotherapy in head and neck cancer \u2013 a dawn to dusk journey","volume":"34","author":"Krishnamurthy","year":"2022","journal-title":"Clin Transl Radiat Oncol"},{"issue":"12","key":"10.1016\/j.radonc.2026.111711_b0085","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1200\/JCO.22.00332","article-title":"Nivolumab plus ipilimumab versus EXTREME regimen as first-line treatment for recurrent\/metastatic squamous cell carcinoma of the head and neck: the final results of CheckMate 651","volume":"41","author":"Haddad","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2026.111711_b0090","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.annonc.2022.12.008","article-title":"Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study","volume":"34","author":"Psyrri","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.radonc.2026.111711_b0095","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.ejca.2015.09.024","volume":"52","author":"Driessen","year":"2016","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.radonc.2026.111711_b0100","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/j.annonc.2020.04.001","article-title":"Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study","volume":"31","author":"Ferris","year":"2020","journal-title":"Ann Oncol"},{"issue":"13","key":"10.1016\/j.radonc.2026.111711_b0105","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1158\/1078-0432.CCR-25-0073","article-title":"INTERLINK-1: a phase III, randomized, placebo-controlled study of monalizumab plus cetuximab in recurrent\/metastatic head and neck squamous cell carcinoma","volume":"31","author":"Fayette","year":"2025","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2026.111711_b0110","doi-asserted-by":"crossref","first-page":"S1592","DOI":"10.1016\/j.annonc.2025.09.060","article-title":"LBA48 BURAN: a phase III study of buparlisib (BUP) plus paclitaxel (PAC) in patients with PD-1(PD-L1)-pretreated recurrent\/metastatic (R\/M) head and neck squamous cell carcinoma (HNSCC)","volume":"36","author":"Soulieres","year":"2025","journal-title":"Ann Oncol"},{"issue":"29","key":"10.1016\/j.radonc.2026.111711_b0115","doi-asserted-by":"crossref","first-page":"3209","DOI":"10.1200\/JCO-25-00272","article-title":"Xevinapant or placebo plus platinum-based chemoradiotherapy in unresected locally advanced squamous cell carcinoma of the head and neck (TrilynX): a randomized, phase III study","volume":"43","author":"Bourhis","year":"2025","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.radonc.2026.111711_b0120","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/j.annonc.2020.07.011","article-title":"Squamous cell carcinoma of the oral cavity, larynx, oropharynx and hypopharynx: EHNS\u2013ESMO\u2013ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Machiels","year":"2020","journal-title":"Ann Oncol"},{"issue":"10212","key":"10.1016\/j.radonc.2026.111711_b0125","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(19)32591-7","article-title":"Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study","volume":"394","author":"Burtness","year":"2019","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.radonc.2026.111711_b0130","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1001\/jama.2023.20181","article-title":"Toripalimab plus chemotherapy for recurrent or metastatic nasopharyngeal carcinoma: The JUPITER-02 randomized clinical trial","volume":"330","author":"Mai","year":"2023","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.radonc.2026.111711_b0135","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa1602252","article-title":"Nivolumab for recurrent squamous-cell carcinoma of the head and neck","volume":"375","author":"Ferris","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.radonc.2026.111711_b0140","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1056\/NEJMoa2415434","article-title":"Neoadjuvant and adjuvant pembrolizumab in locally advanced head and neck cancer","volume":"393","author":"Uppaluri","year":"2025","journal-title":"N Engl J Med"},{"issue":"10526","key":"10.1016\/j.radonc.2026.111711_b0145","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S0140-6736(25)01850-1","article-title":"Nivolumab added to cisplatin and radiotherapy versus cisplatin and radiotherapy alone after surgery for people with squamous cell carcinoma of the head and neck at a high risk of relapse (GORTEC 2018-01 NIVOPOST-OP): a randomised, open-label, phase 3 trial","volume":"407","author":"Bourhis","year":"2026","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.radonc.2026.111711_b0150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.31557\/APJCP.2026.27.1.19","article-title":"From radiation to immune response: a systematic review of systemic immunomodulation in squamous cell head and neck cancer","volume":"27","author":"Valente Ferreira","year":"2026","journal-title":"Asian Pac J Cancer Prev"},{"key":"10.1016\/j.radonc.2026.111711_b0155","doi-asserted-by":"crossref","unstructured":"Huang JJ, Reznik AS, Sonis S, Franzmann EJ, Villa A. Clinical trial termination or withdrawal in head and neck squamous cell carcinoma. JAMA Otolaryngol-- Head Neck Surg. Published online January 2, 2026:e254766. doi:10.1001\/jamaoto.2025.4766.","DOI":"10.1001\/jamaoto.2025.4766"},{"key":"10.1016\/j.radonc.2026.111711_b0160","article-title":"Challenges and opportunities in head and neck cancer research in developing countries: insights from a fireside chat","volume":"11","author":"Chaves","year":"2025","journal-title":"JCO Glob Oncol"},{"key":"10.1016\/j.radonc.2026.111711_b0165","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.e18009","article-title":"Screening failure in clinical trials for patients with head and neck squamous cell carcinoma: a retrospective analysis","volume":"42","author":"Jim\u00e9nez Labaig","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.radonc.2026.111711_b0170","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000032829","article-title":"Use of Delphi in health sciences research: a narrative review","volume":"102","author":"Shang","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"10.1016\/j.radonc.2026.111711_b0175","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0020476","article-title":"Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review","volume":"6","author":"Boulkedid","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.radonc.2026.111711_b0180","doi-asserted-by":"crossref","unstructured":"Andrearczyk V, Oreiller V, Boughdad S, et al. Automatic head and neck tumor segmentation and outcome prediction relying on FDG-PET\/CT images: findings from the second edition of the HECKTOR challenge. Med Image Anal. 2023;90:102972. doi:10.1016\/j.media.2023.102972.","DOI":"10.1016\/j.media.2023.102972"},{"issue":"5","key":"10.1016\/j.radonc.2026.111711_b0185","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1038\/s41431-026-02015-y","article-title":"Priority European strategies for sustainable access to high-quality genetic counselling in cancer: a Delphi study","volume":"34","author":"McCrary","year":"2026","journal-title":"Eur J Hum Genet"},{"issue":"3","key":"10.1016\/j.radonc.2026.111711_b0190","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00355-008-0327-7","article-title":"Relationships between Borda voting and Zermelo ranking","volume":"32","author":"Anderson","year":"2009","journal-title":"Soc Choice Welf"},{"issue":"5","key":"10.1016\/j.radonc.2026.111711_b0195","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41571-022-00603-7","article-title":"HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management","volume":"19","author":"Lechner","year":"2022","journal-title":"Nat RevClin Oncol"},{"issue":"5","key":"10.1016\/j.radonc.2026.111711_b0200","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrc.2018.11","article-title":"The molecular landscape of head and neck cancer","volume":"18","author":"Leemans","year":"2018","journal-title":"Nat Rev Cancer"},{"issue":"24","key":"10.1016\/j.radonc.2026.111711_b0205","first-page":"7350","article-title":"Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma","volume":"62","author":"Ang","year":"2002","journal-title":"Cancer Res"},{"issue":"7536","key":"10.1016\/j.radonc.2026.111711_b0210","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nature14129","article-title":"Comprehensive genomic characterization of head and neck squamous cell carcinomas","volume":"517","author":"Network","year":"2015","journal-title":"Nature"},{"issue":"29","key":"10.1016\/j.radonc.2026.111711_b0215","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2015.62.1086","article-title":"Genetic landscape of human papillomavirus-associated head and neck cancer and comparison to tobacco-related tumors","volume":"33","author":"Hayes","year":"2015","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"25","key":"10.1016\/j.radonc.2026.111711_b0220","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1056\/NEJMoa073770","article-title":"TP53 mutations and survival in squamous-cell carcinoma of the head and neck","volume":"357","author":"Poeta","year":"2007","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.radonc.2026.111711_b0225","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.23.01758","article-title":"For squamous cancers, the streetlamps shine on occasional keys, most baskets are empty, and the umbrellas cannot keep us dry: a call for new models in precision oncology","volume":"42","author":"Hayes","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9","key":"10.1016\/j.radonc.2026.111711_b0230","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1056\/NEJMoa2508820","article-title":"Phase 1 study of rezatapopt, a p53 reactivator, in TP53 Y220C-mutated tumors","volume":"394","author":"Dumbrava","year":"2026","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.radonc.2026.111711_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1101\/gr.241141.118","article-title":"Human papillomavirus and the landscape of secondary genetic alterations in oral cancers","volume":"29","author":"Gillison","year":"2019","journal-title":"Genome Res"},{"issue":"8","key":"10.1016\/j.radonc.2026.111711_b0240","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1093\/jnci\/djz224","article-title":"PIK3CA mutation in HPV-associated OPSCC patients receiving deintensified chemoradiation","volume":"112","author":"Beaty","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.radonc.2026.111711_b0245","article-title":"Clinical validity of a prognostic gene expression cluster-based model in human papillomavirus-positive oropharyngeal carcinoma","volume":"5","author":"Cavalieri","year":"2021","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111711_b0250","doi-asserted-by":"crossref","first-page":"9060","DOI":"10.1038\/s41467-024-53390-3","article-title":"Hallmarks of a genomically distinct subclass of head and neck cancer","volume":"15","author":"Muijlwijk","year":"2024","journal-title":"Nat Commun"},{"issue":"10","key":"10.1016\/j.radonc.2026.111711_b0255","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.radonc.2026.111711_b0260","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/jnci\/djaf249","article-title":"Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection","volume":"118","author":"Das","year":"2026","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.radonc.2026.111711_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104534","article-title":"Tumor-informed ctDNA assay to predict recurrence in locally advanced squamous-cell carcinoma of the head and neck (SCCHN)","volume":"10","author":"Honor\u00e9","year":"2025","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.radonc.2026.111711_b0270","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jamaoto.2025.0923","article-title":"The challenge and promise of circulating tumor HPV DNA for minimal residual disease detection-catching the unseen","volume":"151","author":"Lee","year":"2025","journal-title":"JAMA Otolaryngol- Head Neck Surg"},{"issue":"1","key":"10.1016\/j.radonc.2026.111711_b0275","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijrobp.2008.10.049","article-title":"Prospective trial incorporating pre-\/mid-treatment [18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy","volume":"75","author":"Lee","year":"2009","journal-title":"Int J Radiat Oncol"},{"issue":"8","key":"10.1016\/j.radonc.2026.111711_b0280","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1200\/JCO.23.01308","article-title":"Hypoxia-directed treatment of human papillomavirus\u2013related oropharyngeal carcinoma","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.radonc.2026.111711_b0285","article-title":"Tumor hypoxia on18 F-fluoromisonidazole positron emission tomography and distant metastasis from head and neck squamous cell carcinoma","volume":"7","author":"Gui","year":"2024","journal-title":"JAMANetw Open"},{"key":"10.1016\/j.radonc.2026.111711_b0290","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK_351336","article-title":"Introducing checkpoint inhibitors into the curative setting of head and neck cancers: lessons learned, future considerations","author":"Nenclares","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"1","key":"10.1016\/j.radonc.2026.111711_b0295","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s12967-024-04937-x","article-title":"Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis","volume":"22","author":"Rodrigo","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.radonc.2026.111711_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104709","article-title":"Improving the multidisciplinary therapeutic management of head and neck squamous cell carcinoma: consensus statements from an Italian expert panel","volume":"210","author":"Bossi","year":"2025","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.radonc.2026.111711_b0305","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ejca.2021.09.005","article-title":"Nasopharyngeal cancer in non-endemic areas: impact of treatment intensity within a large retrospective multicentre cohort","volume":"159","author":"Bossi","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111711_b0310","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115749","article-title":"A multicenter retrospective analysis of recurrent\/metastatic nasopharyngeal cancer from non-endemic areas: results in the pre-immunotherapy era","volume":"229","author":"Alberti","year":"2025","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2026.111711_b0315","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2025.115625","article-title":"Longitudinal assessment of plasma EBV-DNA in non-endemic EBV-related nasopharyngeal cancer (NPC): the LEA study","volume":"226","author":"Alfieri","year":"2025","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.radonc.2026.111711_b0320","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41571-021-00524-x","article-title":"Nasopharyngeal carcinoma: an evolving paradigm","volume":"18","author":"Wong","year":"2021","journal-title":"Nat RevClin Oncol"},{"issue":"3","key":"10.1016\/j.radonc.2026.111711_b0325","article-title":"Updates on treatments and management of nasopharyngeal carcinoma","volume":"45","author":"Chua","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.radonc.2026.111711_b0330","doi-asserted-by":"crossref","unstructured":"Huang Y, Sun D, Zhou H, et al. Five-year outcome of camrelizumab plus chemotherapy in recurrent or metastatic nasopharyngeal carcinoma: a secondary analysis of the CAPTAIN-1st randomized clinical trial. JAMA Oncol; 12(3):295-302. doi: 10.1001\/jamaoncol.2025.6245.","DOI":"10.1001\/jamaoncol.2025.6245"},{"key":"10.1016\/j.radonc.2026.111711_b0335","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.6045","article-title":"Tislelizumab plus neoadjuvant chemotherapy and concurrent chemoradiotherapy versus neoadjuvant chemotherapy and concurrent chemoradiotherapy in local advanced nasopharyngeal carcinoma","volume":"42","author":"Luo","year":"2024","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.radonc.2026.111711_b0340","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1001\/jama.2025.13205","article-title":"Toripalimab combination therapy without concurrent cisplatin for nasopharyngeal carcinoma: the DIAMOND randomized clinical trial","volume":"334","author":"The DIAMOND Study Group","year":"2025","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.radonc.2026.111711_b0345","first-page":"483","article-title":"Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study","volume":"24","author":"Xu","year":"2023","journal-title":"LancetOncol"},{"issue":"5","key":"10.1016\/j.radonc.2026.111711_b0350","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/j.ccell.2025.01.014","article-title":"Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: a multicenter phase 2 PLATINUM trial","volume":"43","author":"Xu","year":"2025","journal-title":"Cancer Cell"},{"issue":"10445","key":"10.1016\/j.radonc.2026.111711_b0355","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1016\/S0140-6736(24)00594-4","article-title":"Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial","volume":"403","author":"Liu","year":"2024","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.radonc.2026.111711_b0360","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1001\/jama.2025.1132","article-title":"Adjuvant PD-1 blockade with camrelizumab for nasopharyngeal carcinoma: the DIPPER randomized clinical trial","volume":"333","author":"Liang","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.radonc.2026.111711_b0365","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2025-085863","article-title":"Standard chemoradiotherapy with concurrent and adjuvant camrelizumab in patients with high risk nasopharyngeal carcinoma: multicentre, randomised, open label, phase 3 trial","volume":"392","author":"You","year":"2026","journal-title":"BMJ"},{"key":"10.1016\/j.radonc.2026.111711_b0370","unstructured":"Chen MY. Reduced vs conventional dosage intensity-modulated radiotherapy for chemotherapy-sensitive stage II-III nasopharyngeal carcinoma.; 2020. https:\/\/clinicaltrials.gov\/study\/NCT04448522."},{"issue":"1","key":"10.1016\/j.radonc.2026.111711_b0375","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.23.01296","article-title":"Impact of an epstein-barr virus serology-based screening program on nasopharyngeal carcinoma mortality: a cluster-randomized controlled trial","volume":"43","author":"Chen","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2026.111711_b0380","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113336","article-title":"Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: a single-arm, phase 2 trial","volume":"194","author":"Guo","year":"2023","journal-title":"Eur J Cancer"},{"issue":"11","key":"10.1016\/j.radonc.2026.111711_b0385","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1200\/JCO.22.00099","article-title":"Identifying patients with low-risk locoregionally advanced nasopharyngeal carcinoma by plasma epstein-barr virus DNA for chemotherapy deintensification: Quo Vadis\u00a0?","volume":"40","author":"Ng","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.radonc.2026.111711_b0390","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JCO.21.01467","article-title":"Deintensified chemoradiotherapy for pretreatment epstein-barr virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma: a phase II randomized noninferiority trial","volume":"40","author":"Li","year":"2022","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.radonc.2026.111711_b0395","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3390\/cancers16020383","article-title":"Embracing personalized strategies in radiotherapy for nasopharyngeal carcinoma: beyond the conventional bounds of fields and borders","volume":"16","author":"Yip","year":"2024","journal-title":"Cancers"},{"issue":"5","key":"10.1016\/j.radonc.2026.111711_b0400","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.ijrobp.2023.02.048","article-title":"Systematic review and meta-analysis of the association between radiation therapy treatment volume and patient outcomes","volume":"117","author":"Kyaw","year":"2023","journal-title":"Int J Radiat Oncol"},{"issue":"4","key":"10.1016\/j.radonc.2026.111711_b0405","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ccell.2025.02.002","article-title":"Fragmentomics profiling and quantification of plasma Epstein-Barr virus DNA enhance prediction of future nasopharyngeal carcinoma","volume":"43","author":"Lam","year":"2025","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.radonc.2026.111711_b0410","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.ccell.2024.07.001","article-title":"Longitudinal on-treatment circulating tumor DNA as a biomarker for real-time dynamic risk monitoring in cancer patients: the EP-SEASON study","volume":"42","author":"Lv","year":"2024","journal-title":"Cancer Cell"},{"key":"10.1016\/j.radonc.2026.111711_b0415","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-026-10244-w","article-title":"Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma","author":"Lv","year":"2026","journal-title":"Nature"},{"key":"10.1016\/j.radonc.2026.111711_b0420","doi-asserted-by":"crossref","DOI":"10.1097\/CCO.0000000000001231","article-title":"Circulating epstein-barr virus DNA as a precision biomarker in nasopharyngeal carcinoma: from risk stratification to real-time treatment adaptation and disease surveillance","author":"Zhang","year":"2026","journal-title":"Curr Opin Oncol"},{"issue":"9","key":"10.1016\/j.radonc.2026.111711_b0425","first-page":"e488","article-title":"Target volume delineation of the neck for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas","volume":"26","author":"Tang","year":"2025","journal-title":"LancetOncol"},{"issue":"9","key":"10.1016\/j.radonc.2026.111711_b0430","first-page":"e477","article-title":"Primary target volume delineation for radiotherapy in nasopharyngeal carcinoma: CSTRO, CACA, CSCO, HNCIG, ESTRO, and ASTRO guidelines and contouring atlas","volume":"26","author":"Tang","year":"2025","journal-title":"LancetOncol"},{"issue":"12","key":"10.1016\/j.radonc.2026.111711_b0435","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jamaoncol.2024.4354","article-title":"Ninth version of the AJCC and UICC nasopharyngeal cancer TNM staging classification","volume":"10","author":"Pan","year":"2024","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.radonc.2026.111711_b0440","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaoncol.2020.1808","article-title":"Efficacy and safety of locoregional radiotherapy with chemotherapy vs chemotherapy alone in de novo metastatic nasopharyngeal carcinoma: a multicenter phase 3 randomized clinical trial","volume":"6","author":"You","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.radonc.2026.111711_b0445","unstructured":"Liu Z. Radiotherapy combined With PD-1 monoclonal antibody and capecitabine in the treatment of nasopharyngeal carcinoma; 2022. https:\/\/clinicaltrials.gov\/study\/NCT05290194."},{"key":"10.1016\/j.radonc.2026.111711_b0450","unstructured":"Jingjing M. SBRT and LDRT Combined With PD-1 Antibody and Chemotherapy in r\/m Nasopharyngeal Carcinoma.; 2024. https:\/\/clinicaltrials.gov\/study\/NCT06323239."},{"key":"10.1016\/j.radonc.2026.111711_b0455","unstructured":"Feng J. SBRT combined with chemotherapy and tislelizumab in metastatic NPC.; 2022. https:\/\/clinicaltrials.gov\/study\/NCT05652192."},{"key":"10.1016\/j.radonc.2026.111711_b0460","unstructured":"He X. SBRT for oligo-metastatic lesions after systemic treatment of primary metastatic nasopharyngeal carcinoma; 2020. https:\/\/clinicaltrials.gov\/study\/NCT04351282."},{"key":"10.1016\/j.radonc.2026.111711_b0465","unstructured":"Sui J. The efficacy of camrelizumab plus stereotactic body radiotherapy in R\/M NPC; 2021. https:\/\/clinicaltrials.gov\/study\/NCT04830267."},{"key":"10.1016\/j.radonc.2026.111711_b0470","unstructured":"Chen MY. Whole-target consolidation therapy under systemic therapy for oligometastatic nasopharyngeal carcinoma; 2022. https:\/\/clinicaltrials.gov\/study\/NCT05431764."}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005505?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814026005505?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:36:55Z","timestamp":1790714215000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814026005505"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":94,"alternative-id":["S0167814026005505"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111711","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Integration of radiation therapy with systemic treatments in head and neck cancer: expert opinion and roadmap to consensus","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2026.111711","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111711"}}